New hope for tough leukemia: experimental drug tomivosertib enters human testing
NCT ID NCT05744739
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This early-phase study tests an experimental drug called tomivosertib in 15 adults whose acute myeloid leukemia (AML) has returned or not responded to standard treatments. The main goal is to find the safest and most effective dose by monitoring side effects and any signs that the drug is working. Participants take the drug by mouth daily in 28-day cycles.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.